(MENAFN- EIN Presswire)
The global antifibrinolytic drugs market was valued at $13,593 million in 2018 and is expected to reach $19,333 million by 2026, registering a CAGR of 4.5%.
PORTLAND, OREGON, UNITED STATES, August 17, 2022 /EINPresswire.com / -- Allied Market Research recently published a report, titled, 'Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and industry Forecast, 2019–2026'. According to the report, the global antifibrinolytic drugs industry was pegged at $13.59 billion in 2018 and is projected to reach $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Chief reasons for market fluctuations
Rise in severe road accidents and significant increase in surgical procedures have boosted the growth of the global antifibrinolytic drugs market. However, high cost of these drugs hampers the market growth. On the contrary, untapped potential in developing countries is expected to create lucrative opportunities in the near future.
Request Sample Report at:
By type, the gynaecology segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.
By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.
North America region held the lion's share
The global antifibrinolytic drugs market across North America held the largest share in 2018, contributing to more than two-fifths of the market, owing to surge in surgeries in the region. However, the market across the Asia-Pacific region is expected to register the fastest 6.1% during the forecast period, owing to increase in road accidents in this region.
For Purchase Enquiry at:
Major market players
Xanodyne Pharmaceuticals
ACIC Fine Chems
Aurobindo Pharma Ltd.
Amerigen Pharms Ltd
Akorn
Pfizer (GenMed)
Mylan
Zydus Cadila
Sanofi
Takeda
The gynecology segment dominated the market
The gynecology segment held the largest share in 2018, contributing to nearly one-third of the global antifibrinolytic drugs market, owing to increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. However, the surgeries segment is expected to manifest the fastest CAGR of 5.9% during the study period, owing to significant increase in the number of surgeries being performed across the globe.
The trauma centers segment to manifest the fastest growth
The trauma center segment is anticipated to portray the fastest CAGR of 5.1% during the forecast period, owing to remarkable increase in road accidents globally. However, the hospitals and clinics segment held the largest share in 2018, accounting for nearly half of the global antifibrinolytic drugs market share. This is due to increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.
Simply Speak To Analyst In A Single Click:
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions.' AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
MENAFN17082022003118003196ID1104714022
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.